Filed by CytRx Corporation
pursuant to Rule 425 of the Securities Act of 1933, as amended
Subject Company: CytRx Corporation
Subject Company’s Commission File No.: 000-15327
On
August 13, 2008, CytRx Corporation issued the following press release:
CytRx Corporation CEO to be Interviewed Live on “Steve Crowley’s American Scene” National Financial
Talk Radio Show
LOS ANGELES—August 13, 2008 — CytRx Corporation (Nasdaq: CYTR) ), a biopharmaceutical company
engaged in the development and commercialization of therapeutics based on molecular chaperone
amplification technology, is pleased to announce that its President and CEO, Steven A. Kriegsman,
will be interviewed on Friday, August 15, 2008, on “Steve Crowley’s American Scene” National Radio
Show at 10:24 A.M. EDT.
This interview can be heard live on BusinessTalkRadioNetwork(R) affiliate radio stations across the
U.S.A. and also streamed on the website: www.businesstalkradio.net plus other affiliates
nationwide, plus on the website www.americansceneradio.com. You can find local radio
stations by accessing the website, as well. Mr. Kriegsman is being scheduled for future interviews
on American Scene, as part of the daily Investors’ Showcase segments where he will update listeners
on CytRx’s activities.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the
development of therapeutics based on molecular chaperone amplification. The Company owns three
clinical-stage compounds based on its small-molecule molecular chaperone amplification technology.
CytRx has a research and development facility in San Diego. CytRx has agreed to acquire Innovive
Pharmaceuticals, Inc., a biopharmaceutical company with four drug candidates for oncology, in a
transaction that is expected to close this quarter. CytRx currently owns a 45% equity interest in
RXi Pharmaceuticals Corporation (Nasdaq: RXII). For more information on the Company, visit
www.CytRx.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that
could cause actual events or results to differ materially from the events or results described in
the forward-looking statements, including risks or uncertainties related to CytRx’s business and to
the proposed acquisition of Innovive Pharmaceuticals, Inc., as well as other risks and
uncertainties described in CytRx’s Form 10-Q for the quarter ended June 30, 2008 and other recently
filed SEC documents, such as its most recent annual report on Form 10--K. The business and
operations of RXi, as well as CytRx’s ownership of RXi shares, also are subject to risks and
uncertainties, including those set forth in RXi’s filings with the SEC. All forward-looking
statements are based upon information available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
# # #
In connection with the proposed Innovive acquisition, CytRx has filed with the SEC a registration
statement on Form S-4, which includes a prospectus/proxy statement of CytRx and Innovive relating
to the merger. INVESTORS AND STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE PROSPECTUS/PROXY
STATEMENT, BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and stockholders may obtain a free
copy of the prospectus/proxy statement and other documents filed by us and Innovive at the SEC’s
website at http://www.sec.gov.
1
This communication does not constitute an offer to sell or the solicitation of an offer to sell or
the solicitation of an offer to buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such jurisdiction. No offering of securities will be
made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act
of 1933, as amended.
This communication is not a solicitation of a proxy from any stockholder of Innovive. However,
CytRx, Innovive and their respective officers and directors may be deemed to be participants in the
solicitation of proxies from Innovive stockholders in connection with the proposed Innovive
acquisition. Information about the officers and directors of CytRx and their ownership of CytRx
common stock is set forth in the proxy statement for CytRx’s 2008 Annual Meeting of Stockholders,
which was filed with the SEC on May 23, 2008. Information about the officers and directors of
Innovive and their ownership of Innovive common stock is set forth in Innovive’s most recent Annual
Report on Form 10-K, which was filed with the SEC on March 31, 2008 and amended on April 29, 2008.
Investors and stockholders may obtain additional information regarding the direct and indirect
interests of CytRx, Innovive and their respective officers and directors in the proposed
acquisition by reading the prospectus/proxy statement referred to above.
CONTACT: CytRx Corporation
Porter Novelli Life Sciences
Investors:
Parag Dave, 212-601-8186
pdave@pnlifesciences.com
Media:
Cory Tromblee, 617-897-8294
ctromblee@pnlifesciences.com
SOURCE: CytRx Corporation
2